Table 4.
Subsequent therapy.
| Subsequent therapy | N=79 |
|---|---|
| TKI | 8 (10.1) |
| PD-1 | 5 (6.3) |
| HAIC | 5 (6.3) |
| TKI+PD-1 | 30 (37.9) |
| MWA+TACE | 1 (1.3) |
| RFA+ Radiotherapy | 1 (1.3) |
| TACE+ TKI+PD-1 | 9 (11.4) |
| HAIC+ TKI+PD-1 | 8 (10.1) |
| MWA+ TKI+PD-1 | 1 (1.3) |
| TKI+PD-1+ Radiotherapy | 3 (3.8) |
| HAIC+TACE+ TKI+PD-1 | 4 (5.0) |
| TACE+ TKI+PD-1+Radiotherapy | 1 (1.3) |
| TACE+ TKI+PD-1+Radiotherapy | 1 (1.3) |
| MWA+ TKI+PD-1+ Radiotherapy | 1 (1.3) |
| HAIC+TACE+ TKI+PD-1+Radiotherapy | 1 (1.3) |
TKIs, tyrosine kinase inhibitors; PD-1, programmed cell death protein-1; HAIC, hepatic arterial infusion chemotherapy; MWA, microwave ablation; TACE, transcatheter arterial chemoembolization. RFA, radiofrequency ablation.